Old Web
English
Sign In
Acemap
>
authorDetail
>
F Anthony Greco
F Anthony Greco
Seattle Children's Research Institute
Pharmacodynamics
PI3K/mTOR Inhibitor BEZ235
Dosing
PK/PD models
Cmax
2
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
KRAS subset analysis from randomized phase II trials of erlotinib versus erlotinib plus sorafenib or pazopanib in refractory non-small cell lung cancer (NSCLC).
2017
Journal of Clinical Oncology
D. M. Waterhouse
Dawn Michelle Stults
Davey B. Daniel
Paula L. Griner
F Anthony Greco
Howard A. Burris
John D. Hainsworth
David R. Spigel
Show All
Source
Cite
Save
Citations (2)
Abstract A166: A Phase I pharmacokinetic/pharmacodynamic (PK/PD) study of the sachet formulation of the oral dual PI3K-mTOR inhibitor BEZ235 given twice daily (BID) in patients (pts) with advanced solid tumors.
2013
Molecular Cancer Therapeutics
Johanna C. Bendell
Carla Kurkjian
Jeffrey R. Infante
Todd Michael Bauer
Howard A. Burris
David R. Spigel
Denise A. Yardley
F Anthony Greco
Kent C. Shih
Dana S. Thompson
Suzanne F. Jones
Show All
Source
Cite
Save
Citations (0)
1